Insider selling
Traded Dec 19, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan
An Aim Immunotech director sold $884 of Aim Immunotech shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 20, 2024 · Filed Nov 20, 2024
The CEO of Aim Immunotech paid $11K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$11,000
Shares × reported transaction price
<$25K
+4.0%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the CEO's reported total pay for fiscal 2023 ($1.43M)
Purchase value ÷ the CEO's total from the Summary Compensation Table, as tagged in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-09-30. The proxy names Thomas K. Equels as CEO for that year. A size comparison, not a judgement
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +8.7% | +1.5% | +7.2% |
| 30 days | −11.4% | +0.2% | −11.6% |
| 90 days | −36.7% | +3.2% | −40.0% |
| 365 days | +547.1% | +11.0% | +536.1% |
Past results only. Not a forecast.
Insider selling
Traded Dec 19, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan
An Aim Immunotech director sold $884 of Aim Immunotech shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Dec 18, 2024 · filed 1 day later
The CEO of Aim Immunotech paid $4.7K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month.
Insider buying
Traded Dec 2, 2024 · filed 2 days later
An Aim Immunotech director paid $2.4K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month.
Thomas K Equels, CEO & President's past purchases, 90 days after disclosure: 5 buys, median −40.0 pts vs S&P 500, beat it 0 of 5 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.